Franklin Genomic Advancements ETF (BATS:HELX) Shares Bought by Harbour Investments Inc.

Harbour Investments Inc. raised its stake in Franklin Genomic Advancements ETF (BATS:HELX) by 1,240.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,823 shares of the company’s stock after purchasing an additional 1,687 shares during the period. Harbour Investments Inc. owned about 0.46% of Franklin Genomic Advancements ETF worth $49,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Halbert Hargrove Global Advisors LLC raised its position in Franklin Genomic Advancements ETF by 41.8% in the 1st quarter. Halbert Hargrove Global Advisors LLC now owns 2,554 shares of the company’s stock valued at $69,000 after purchasing an additional 753 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Franklin Genomic Advancements ETF in the 4th quarter valued at about $230,000. LPL Financial LLC increased its holdings in shares of Franklin Genomic Advancements ETF by 19.5% in the 4th quarter. LPL Financial LLC now owns 16,965 shares of the company’s stock valued at $489,000 after acquiring an additional 2,768 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Franklin Genomic Advancements ETF in the 4th quarter valued at about $1,184,000.

Franklin Genomic Advancements ETF Stock Performance

HELX opened at $27.87 on Friday. Franklin Genomic Advancements ETF has a one year low of $23.74 and a one year high of $33.93. The company has a market cap of $11.15 million, a P/E ratio of 26.71 and a beta of 1.05. The business’s 50-day simple moving average is $27.60 and its 200-day simple moving average is $27.69.

About Franklin Genomic Advancements ETF

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.